Swaminathan Padmanabhan Iyer, MD

Professor of Medicine, Institute for Academic Medicine
Houston Methodist
Weill Cornell Medical College


Dr. Iyer is a Hematologist/Oncologist and has extensive expertise in early phase clinical studies including several first in human anticancer agents; he was part of pivotal studies that led to the FDA approval of the new anti-CD20 monoclonal antibody Ofatumumab or Arzerra in Chronic Lymphocytic Leukemia and the Histone Deacetylase inhibitor Romidepsin or Istodax in Peripheral T cell Lymphomas. Dr. Iyer has won numerous awards including Outstanding Volunteer Physician for 2010 by the Leukemia Lymphoma Society and has been listed as one of America’s Top Physicians since 2007.

Dr. Iyer received his MB, BS, from Bangalore Medical College, India. He completed his internship and residency in medicine at Wayne State University; and Fellowship in Hematology/Medical Oncology at the Sylvester Comprehensive Cancer Center, University of Miami, Florida. Soon after his fellowship, he spent many years at the Roswell Park Cancer Institute as the staff physician in Lymphoma at the Myeloma Care Center and participated in the Blood and Marrow Transplant Program. He then worked as the Director of Hematological Malignancies at the Cancer Therapy & Research Center, UTHSC, San Antonio before moving to Houston Methodist.

Dr. Iyer is a Diplomat of the American Board of Internal Medicine and is board certified in Internal Medicine, Hematology and Medical Oncology. He is currently the Leader of the Early Drug Development Program in Oncology and Hematology, and Co-Director of the Malignant Hematology Program. Dr. Iyer has extensive expertise in early phase clinical studies including several first in human anticancer agents.

Areas Of Expertise

Hematology Leukemia Malignant Early Drug Development Lymphoma

Cross Talk between Radiation and Immunotherapy: The Twain Shall Meet
Iyer, SP, Hunt, CR & Pandita, TK 2017, Radiation Research. DOI: 10.1667/RR14941.1

Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges
Gentille, C, Qin, Q, Barbieri, A, Pingali, SR & Iyer, S 2017, ecancermedicalscience, vol 11, 771. DOI: 10.3332/ecancer.2017.771

Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis – a retrospective study from a tertiary center
Nan, X, Qin, Q, Gentille, C, Ensor, J, Leveque, C, Pingali, R, Phan, AT, Rice, L & Iyer, S 2017, Leukemia and Lymphoma, pp. 1-11. DOI: 10.1080/10428194.2016.1277386

Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: Bridging the gap 2015, Beijing, China
Huang, XJ, Liu, K, Ritchie, D, Andersson, B, Lu, J, Hou, J, Burguera, ADLF, Wang, JX, Yeoh, A, Yan, C, Zhou, D, Tan, D, Kim, DW, Wu, D, Shpall, E, Kornblau, S, Neelapu, S, Hongeng, S, Li, J, Hu, J, Zhang, LS, Wang, M, Malhotra, P, Jiang, Q, Qin, Y, Wong, R, Champlin, R, Hagemeister, F, Westin, J, Iyer, S, Mathews, V, Wang, Y, Hu, Y, Xiao, Z, Shao, Z, Orlowski, RZ, Chim, CS, Mulligan, S, Sanz, M, Ozawa, K, Parmar, S & Issaragrisil, S 2017, Oncotarget, vol 8, no. 25, pp. 41620-41630. DOI: 10.18632/oncotarget.15655

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy
Jewell, RC, Kipps, TJ, Dürig, J, Griskevicius, L, Stilgenbauer, S, Smolej, L, Mayer, J, Hess, G, Hernandez-Ilizaliturri, FJ, Padmanabhan-Iyer, S, Fang, L, Goldstein, N, Gorczyca, M, Gupta, I, Lisby, S & Wierda, WG 2016, Leukemia and Lymphoma, pp. 1-9. DOI: 10.1080/10428194.2016.1195497

Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
Pro, B, Horwitz, SM, Prince, HM, Foss, FM, Sokol, L, Greenwood, M, Caballero, D, Morschhauser, F, Wilhelm, M, Iyer, SP, Shustov, AR, Wolfson, J, Balser, BE & Coiffier, B 2016, Hematological Oncology. DOI: 10.1002/hon.2320

Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China
Lu, J, Hou, J, Liu, KY, Parmar, S, De La Fuente, A, Andersson, B, Yan, C, Zhou, D, Tan, D, Ritchie, D, Wu, D, Shpall, E, Laport, GG, Li, J, Hu, J, Zhang, LS, Wang, M, Malhotra, P, Jiang, Q, Qin, Y, Wong, R, Champlin, R, Issaragrisil, S, Iyer, S, Mathews, V, Wang, Y, Hu, Y, Xiao, Z, Shao, Z, Rosengarten, R, Steuernagle, J, Xiao, JH, Orlowski, R & Chim, JCS 2016, Leukemia and Lymphoma, pp. 1-5. DOI: 10.3109/10428194.2015.1135434

A unique aptamer-drug conjugate for targeted therapy of multiple myeloma
Wen, J, Tao, W, Hao, S, Iyer, SP & Zu, Y 2016, Leukemia, vol 30, no. 4, pp. 987-91. DOI: 10.1038/leu.2015.216

Results of the phase 1 trial of RG7112, a small-molecule MDM2 antagonist in leukemia
Andreeff, M, Kelly, KR, Yee, K, Assouline, S, Strair, R, Popplewell, L, Bowen, D, Martinelli, G, Drummond, MW, Vyas, P, Kirschbaum, M, Iyer, SP, Ruvolo, V, Gonzalez, GMN, Huang, X, Chen, G, Graves, B, Blotner, S, Bridge, P, Jukofsky, L, Middleton, S, Reckner, M, Rueger, R, Zhi, J, Nichols, G & Kojima, K 2016, Clinical Cancer Research, vol 22, no. 4, pp. 868-876. DOI: 10.1158/1078-0432.CCR-15-0481

HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist
Devaraj, SGT, Fiskus, W, Shah, B, Qi, J, Sun, B, Iyer, SP, Sharma, S, Bradner, JE & Bhalla, KN 2016, Leukemia, vol 30, no. 2, pp. 504-508. DOI: 10.1038/leu.2015.142

Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-hodgkin lymphoma: Final analysis of the GAUSS study
Sehn, LH, Goy, A, Offner, FC, Martinelli, G, Caballero, MD, Gadeberg, O, Baetz, T, Zelenetz, AD, Gaidano, G, Fayad, LE, Buckstein, R, Friedberg, JW, Crump, M, Jaksic, B, Zinzani, PL, Iyer, SP, Sahin, D, Chai, A, Fingerle-Rowson, G & Press, OW 2015, Journal of Clinical Oncology, vol 33, no. 30, pp. 3467-3474. DOI: 10.1200/JCO.2014.59.2139

Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia
Zhao, N, Pei, SN, Qi, J, Zeng, Z, Iyer, SP, Lin, P, Tung, CH & Zu, Y 2015, Biomaterials, vol 67, pp. 42-51. DOI: 10.1016/j.biomaterials.2015.07.025

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: Final results from a pivotal study
Österborg, A, Jewell, RC, Padmanabhan-Iyer, S, Kipps, TJ, Mayer, J, Stilgenbauer, S, Williams, CD, Hellmann, A, Furman, RR, Robak, T, Hillmen, P, Trnêný, M, Dyer, MJS, Piotrowska, M, Kozak, T, Gupta, IV, Phillips, JL, Goldstein, N, Struemper, H, Losic, N, Lisby, S & Wierda, WG 2015, Haematologica, vol 100, no. 8. DOI: 10.3324/haematol.2014.121459

Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma
Seggewiss-Bernhardt, R, Bargou, RC, Goh, YT, Stewart, AK, Spencer, A, Alegre, A, Bladé, J, Ottmann, OG, Fernandez-Ibarra, C, Lu, H, Pain, S, Akimov, M & Iyer, SP 2015, Cancer, vol 121, no. 13, pp. 2185-2192. DOI: 10.1002/cncr.29339

Romidepsin for the treatment of peripheral t-cell lymphoma
Iyer, SP & Foss, FF 2015, Oncologist, vol 20, no. 9, pp. 1084-1091. DOI: 10.1634/theoncologist.2015-0043

Pre-clinical efficacy of combined therapy with novel ß-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells
Fiskus, W, Sharma, S, Saha, S, Shah, B, Devaraj, SGT, Sun, B, Horrigan, S, Leveque, C, Zu, Y, Iyer, S & Bhalla, KN 2015, Leukemia, vol 29, no. 6, pp. 1267-1278. DOI: 10.1038/leu.2014.340

Utility of <sup>18</sup>fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma
Horwitz, S, Coiffier, B, Foss, F, Prince, HM, Sokol, L, Greenwood, M, Caballero, D, Morschhauser, F, Pinter-Brown, L, Iyer, SP, Shustov, A, Nichols, J, Balser, J, Balser, B & Pro, B 2015, Annals of Oncology, vol 26, no. 4, pp. 774-779. DOI: 10.1093/annonc/mdv010

Erratum: WTAP is a novel oncogenic protein in acute myeloid leukemia (Leukemia (2014) 28 (1171-1174) DOI: 10.1038/leu.2014.16)
Bansal, H, Yihua, Q, Iyer, SP, Ganapathy, S, Proia, DA, Penalva, LO, Uren, PJ, Suresh, U, Carew, JS, Karnad, AB, Weitman, S, Tomlinson, GE, Rao, MK, Kornblau, SM & Bansal, S 2014, Leukemia, vol 28, no. 12, pp. 2427. DOI: 10.1038/leu.2014.290

BET protein antagonist JQ1 is synergistically lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD
Fiskus, W, Sharma, S, Qi, J, Shah, B, Devaraj, SGT, Leveque, C, Portier, BP, Iyer, S, Bradner, JE & Bhalla, KN 2014, Molecular Cancer Therapeutics, vol 13, no. 10, pp. 2315-2327. DOI: 10.1158/1535-7163.MCT-14-0258

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
Fiskus, W, Sharma, S, Shah, B, Portier, BP, Devaraj, SGT, Liu, K, Iyer, SP, Bearss, D & Bhalla, KN 2014, Leukemia. DOI: 10.1038/leu.2014.119